Development of zafirlukast analogues for improved anti-thrombotic activity through thiol isomerase inhibition

Download

[thumbnail of 25.2.12 ATVB Final Submission Manuscript and Supplemental.pdf]

Text - Accepted Version
· Restricted to Repository staff only

Restricted to Repository staff only

Advice

Please see our End User Agreement.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

Tools

Lists

Keovilay, J. A., Howard, K. C., Taylor, K. A. ORCID: https://orcid.org/0000-0002-4599-7727, Khan, S., Wurl, S. E., Szahaj, M. K., Sage, T., Chandrika, N. T., Hou, C., Tsodikov, O. V., Gibbins, J. M. ORCID: https://orcid.org/0000-0002-0372-5352, Garneau-Tsodikova, S. and Kennedy, D. R. (2025) Development of zafirlukast analogues for improved anti-thrombotic activity through thiol isomerase inhibition. Arteriosclerosis Thrombosis and Vascular Biology. ISSN 1524-4636 doi: 10.1161/ATVBAHA.124.321579

Abstract/Summary

Background: Thiol isomerases play essential and non-redundant roles in platelet activation, aggregation, and thrombus formation. Thiol isomerase inhibitors have the potential to overcome the two major drawbacks of current antithrombotic therapies, as they target both arterial and venous thrombosis without enhancing bleeding risks. Recently, an FDA-approved drug, zafirlukast (ZAF), was shown to be a promising pan-thiol isomerase inhibitor. The objective of this study is to develop analogues of ZAF with optimized thiol isomerase inhibition and antithrombotic activity. Methods: 35 ZAF analogues were tested in an insulin turbidometric assay for thiol isomerase inhibition. Analogues were tested for platelet activation, aggregation, P-selectin expression, and laser-induced thrombosis in mice and compared with the parent compound. Results: Of the 35 analogues, 12 retained activity, with one, compound 21 that demonstrated a greater potency than that of ZAF, 5 had a similar potency to that of ZAF, and 6 had a weaker potency. Analogues demonstrated inhibition of platelet aggregation and P-selectin expression as compared to ZAF, consistent with their potencies. ZAF and compound 21 were shown to be reversible inhibitors of thiol isomerases, and not cytotoxic to cultured, lung, liver, and kidney cells. Finally, in an in vivo assessment of thrombus formation, compound 21 was able to significantly inhibit thrombus formation without affecting bleeding times. Conclusions: A ZAF analogue, compound 21, with properties superior to those of ZAF was synthesized, demonstrating improved inhibition of platelet activation, aggregation, and thrombus formation as compared to the parent ZAF. This approach could yield a promising clinical candidate for treatment and prophylaxis of arterial and venous thrombosis.

Altmetric Badge

Item Type	Article
URI	https://reading-clone.eprints-hosting.org/id/eprint/120916
Identification Number/DOI	10.1161/ATVBAHA.124.321579
Refereed	Yes
Divisions	Interdisciplinary centres and themes > Institute for Cardiovascular and Metabolic Research (ICMR) Life Sciences > School of Biological Sciences > Biomedical Sciences
Uncontrolled Keywords	Drug repurposing, Zafirlukast, PDI, Structure-activity relationship, Thiol isomerase, Thrombosis.
Publisher	American Heart Association
Download/View statistics	View download statistics for this item

Deposit Details

Date Deposited:	21 Feb 2025 14:56	Date item deposited into CentAUR
Last Modified:	23 Mar 2025 04:34	Date item last modified

References

1. Furie B, Furie BC. Formation of the clot. Thromb Res. 2012;130 Suppl 1:S44-S46. doi: 10.1016/j.thromres.2012.08.272 2. Holbrook LM, Keeton SJ, Sasikumar P, Nock S, Gelzinis J, Brunt E, Ryan S, Pantos MM, Verbetsky CA, Gibbins JM, et al. Zafirlukast is a broad-spectrum thiol isomerase inhibitor that inhibits thrombosis without altering bleeding times. Br J Pharmacol. 2021;178:550-563. doi: 10.1111/bph.15291 3. Stoll G, Kleinschnitz C, Nieswandt B. Molecular mechanisms of thrombus formation in ischemic stroke: Novel insights and targets for treatment. Blood. 2008;112:3555-3562. doi: 10.1182/blood-2008-04-144758 4. Schror K. Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost. 1997;23:349-356. doi: 10.1055/s-2007-996108 5. Hartwig J, Italiano J, Jr. The birth of the platelet. J Thromb Haemost. 2003;1:1580-1586. doi: 10.1046/j.1538-7836.2003.00331.x 6. Patel S, Singh R, Preuss CV, Patel N. Warfarin. In: StatPearls. Treasure Island (FL); 2022. 7. Heit JA. Venous thromboembolism: Disease burden, outcomes and risk factors. J Thromb Haemost. 2005;3:1611-1617. doi: 10.1111/j.1538-7836.2005.01415.x 8. Sorensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, Olsen JH. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000;95:2218-2224. doi: 10.1111/j.1572-0241.2000.02248.x 9. Jasuja R, Passam FH, Kennedy DR, Kim SH, van Hessem L, Lin L, Bowley SR, Joshi SS, Dilks JR, Furie B, et al. Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. J Clin Invest. 2012;122:2104-2113. doi: 10.1172/JCI61228 10. Zwicker JI, Schlechter BL, Stopa JD, Liebman HA, Aggarwal A, Puligandla M, Caughey T, Bauer KA, Kuemmerle N, Wong E, et al. Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight. 2019;4:e125851. doi: 10.1172/jci.insight.125851 11. Flaumenhaft R, Furie B. Vascular thiol isomerases. Blood. 2016;128:893-901. doi: 10.1182/blood-2016-04-636456 12. Schulman S, Bendapudi P, Sharda A, Chen V, Bellido-Martin L, Jasuja R, Furie BC, Flaumenhaft R, Furie B. Extracellular thiol isomerases and their role in thrombus formation. Antioxid Redox Signal. 2016;24:1-15. doi: 10.1089/ars.2015.6530 13. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359:938-949. doi: 10.1056/NEJMra0801082 14. Holbrook LM, Sasikumar P, Stanley RG, Simmonds AD, Bicknell AB, Gibbins JM. The platelet-surface thiol isomerase enzyme ERp57 modulates platelet function. J Thromb Haemost. 2012;10:278-288. doi: 10.1111/j.1538-7836.2011.04593.x 15. Holbrook LM, Sandhar GK, Sasikumar P, Schenk MP, Stainer AR, Sahli KA, Flora GD, Bicknell AB, Gibbins JM. A humanized monoclonal antibody that inhibits platelet-surface ERp72 reveals a role for ERp72 in thrombosis. J Thromb Haemost. 2018;16:367-377. doi: 10.1111/jth.13878 16. Jordan PA, Stevens JM, Hubbard GP, Barrett NE, Sage T, Authi KS, Gibbins JM. A role for the thiol isomerase protein ERP5 in platelet function. Blood. 2005;105:1500-1507. doi: 10.1182/blood-2004-02-0608 17. Essex DW, Li M. Protein disulphide isomerase mediates platelet aggregation and secretion. Br J Haematol. 1999;104:448-454. doi: 10.1046/j.1365-2141.1999.01197.x 18. Lahav J, Jurk K, Hess O, Barnes MJ, Farndale RW, Luboshitz J, Kehrel BE. Sustained integrin ligation involves extracellular free sulfhydryls and enzymatically catalyzed disulfide exchange. Blood. 2002;100:2472-2478. doi: 10.1182/blood-2001-12-0339 19. Zhou J, Wu Y, Rauova L, Koma G, Wang L, Poncz M, Li H, Liu T, Fong KP, Bennett JS, et al. A novel role for endoplasmic reticulum protein 46 (ERp46) in platelet function and arterial thrombosis in mice. Blood. 2022;139:2050-2065. doi: 10.1182/blood.2021012055 20. Wang L, Wu Y, Zhou J, Ahmad SS, Mutus B, Garbi N, Hammerling G, Liu J, Essex DW. Platelet-derived ERp57 mediates platelet incorporation into a growing thrombus by regulation of the alphaIIbbeta3 integrin. Blood. 2013;122:3642-3650. doi: 10.1182/blood-2013-06-506691 21. Zhou J, Wu Y, Wang L, Rauova L, Hayes VM, Poncz M, Essex DW. The disulfide isomerase ERp57 is required for fibrin deposition in vivo. J Thromb Haemost. 2014;12:1890-1897. doi: 10.1111/jth.12709 22. Zhou J, Wu Y, Chen F, Wang L, Rauova L, Hayes VM, Poncz M, Li H, Liu T, Liu J, et al. The disulfide isomerase ERp72 supports arterial thrombosis in mice. Blood. 2017;130:817-828. doi: 10.1182/blood-2016-12-755587 23. Spector SL. Management of asthma with zafirlukast. Clinical experience and tolerability profile. Drugs. 1996;52 Suppl 6:36-46. doi: 10.2165/00003495-199600526-00007 24. Gelzinis JA, Szahaj MK, Bekendam RH, Wurl SE, Pantos MM, Verbetsky CA, Dufresne A, Shea M, Howard KC, Tsodikov OV, et al. Targeting thiol isomerase activity with zafirlukast to treat ovarian cancer from the bench to clinic. FASEB J. 2023;37:e22914. doi: 10.1096/fj.202201952R 25. Howard KC, Gonzalez OA, Garneau-Tsodikova S. Second generation of zafirlukast derivatives with improved activity against the oral pathogen Porphyromonas gingivalis. ACS Med Chem Lett. 2020;11:1905-1912. doi: 10.1021/acsmedchemlett.9b00614 26. Howard KC, Garneau-Tsodikova S. Selective Inhibition of the Periodontal Pathogen Porphyromonas gingivalis by Third-Generation Zafirlukast Derivatives. J Med Chem. 2022;65:14938-14956. doi: 10.1021/acs.jmedchem.2c01471 27. Thamban Chandrika N, Fosso MY, Alimova Y, May A, Gonzalez OA, Garneau-Tsodikova S. Novel zafirlukast derivatives exhibit selective antibacterial activity against Porphyromonas gingivalis. MedChemComm. 2019;10:926-933. doi: 10.1039/c9md00074g 28. Xu S, Butkevich AN, Yamada R, Zhou Y, Debnath B, Duncan R, Zandi E, Petasis NA, Neamati N. Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proc Natl Acad Sci, U S A. 2012;109:16348-16353. doi: 10.1073/pnas.1205226109 29. Falati S, Patil S, Gross PL, Stapleton M, Merrill-Skoloff G, Barrett NE, Pixton KL, Weiler H, Cooley B, Newman DK, et al. Platelet PECAM-1 inhibits thrombus formation in vivo. Blood. 2006;107:535-541. doi: 10.1182/blood-2005-04-1512 30. Bernstein PR. Chemistry and structure-activity relationships of leukotriene receptor antagonists. Am J Respir Crit Care Med. 1998;157:S220-226. 31. Dong G, Wearsch PA, Peaper DR, Cresswell P, Reinisch KM. Insights into MHC class I peptide loading from the structure of the tapasin-ERp57 thiol oxidoreductase heterodimer. Immunity. 2009;30:21-32. doi: 10.1016/j.immuni.2008.10.018 32. Fischer JD, Song MH, Suttle AB, Heizer WD, Burns CB, Vargo DL, Brouwer KL. Comparison of zafirlukast (Accolate) absorption after oral and colonic administration in humans. Pharm Res. 2000;17:154-159. doi: 10.1023/a:1007509112383 33. Virchow JC, Jr., Prasse A, Naya I, Summerton L, Harris A. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med. 2000;162:578-585. doi: 10.1164/ajrccm.162.2.9905041 34. Hasegawa S, Ichiyama T, Hashimoto K, Suzuki Y, Hirano R, Fukano R, Furukawa S. Functional expression of cysteinyl leukotriene receptors on human platelets. Platelets. 2010;21:253-259. doi: 10.3109/09537101003615394 35. Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, Coulombe N, Abramovitz M, Figueroa DJ, Zeng Z, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999;399:789-793. doi: 10.1038/21658 36. Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, Stocco R, Bellefeuille JN, Abramovitz M, Cheng R, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem. 2000;275:30531-30536. doi: 10.1074/jbc.M003490200 37. Cummings HE, Liu T, Feng C, Laidlaw TM, Conley PB, Kanaoka Y, Boyce JA. Cutting edge: Leukotriene C4 activates mouse platelets in plasma exclusively through the type 2 cysteinyl leukotriene receptor. J Immunol. 2013;191:5807-5810. doi: 10.4049/jimmunol.1302187 38. Dhaliwal A, Bajaj T. Zafirlukast. In: StatPearls. Treasure Island (FL); 2024. 39. Powell LE, Foster PA. Protein disulphide isomerase inhibition as a potential cancer therapeutic strategy. Cancer Med. 2021;10:2812-2825. doi: 10.1002/cam4.3836 40. Krajewski D, Polukort SH, Gelzinis J, Rovatti J, Kaczenski E, Galinski C, Pantos M, Shah NN, Schneider SS, Kennedy DR, et al. Protein disulfide isomerases regulate IgE-mediated mast cell responses and their inhibition confers protective effects during food allergy. Front Immunol. 2020;11:606837. doi: 10.3389/fimmu.2020.606837 41. Essex DW, Li M, Miller A, Feinman RD. Protein disulfide isomerase and sulfhydryl-dependent pathways in platelet activation. Biochemistry. 2001;40:6070-6075. doi: 10.1021/bi002454e 42. Lovat PE, Corazzari M, Armstrong JL, Martin S, Pagliarini V, Hill D, Brown AM, Piacentini M, Birch-Machin MA, Redfern CP. Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress. Cancer Res. 2008;68:5363-5369. doi: 10.1158/0008-5472.CAN-08-0035 43. Bendapudi PKB, R. H.; Lin, L.; Huang, M.; Furie, B.; Flaumenhaft, R. ML359, a Small Molecule Inhibitor of Protein Disulfide Isomerase That Prevents Thrombus Formation and Inhibits Oxidoreductase but not Transnitrosylase Activity. Blood. 2014;124:2880. 44. Khodier C, VerPlank L, Nag PP, Pu J, Wurst J, Pilyugina T, Dockendorff C, Galinski CN, Scalise AA, Passam F, et al. Identification of ML359 as a Small Molecule Inhibitor of Protein Disulfide Isomerase. In: Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD); 2010. 45. Ozcelik D, Pezacki JP. Small Molecule Inhibition of Protein Disulfide Isomerase in Neuroblastoma Cells Induces an Oxidative Stress Response and Apoptosis Pathways. ACS Chem Neurosci. 2019;10:4068-4075. doi: 10.1021/acschemneuro.9b00301 46. Uehara T, Nakamura T, Yao D, Shi ZQ, Gu Z, Ma Y, Masliah E, Nomura Y, Lipton SA. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature. 2006;441:513-517. doi: 10.1038/nature04782 47. Diwaker D, Mishra KP, Ganju L, Singh SB. Protein disulfide isomerase mediates dengue virus entry in association with lipid rafts. Viral Immunol. 2015;28:153-160. doi: 10.1089/vim.2014.0095 48. Walczak CP, Tsai B. A PDI family network acts distinctly and coordinately with ERp29 to facilitate polyomavirus infection. J Virol. 2011;85:2386-2396. doi: 10.1128/JVI.01855-10 49. Gallina A, Hanley TM, Mandel R, Trahey M, Broder CC, Viglianti GA, Ryser HJ. Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry. J Biol Chem. 2002;277:50579-50588. doi: 10.1074/jbc.M204547200

University Staff: Request a correction | Centaur Editors: Update this record

Search Google Scholar